While GLP-1 receptor (GLP-1R) agonists are approved for weight loss, scant information is obtainable whether this class of drugs is reliable and beneficial in SARS-CoV-2-infected people with obesity, needless to say the necessity of the safety profiles of other glucose-lowering agents in people with clinical symptoms of COVID-19. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.